We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.

September 16, 2022

How to Overcome the Blockers to DTx Adoption and Measure Success

Commentary
HealthXL Team & HealthXL Community
&

The HealthXL Sprint 2-part meeting series connects senior leaders across our community to solve the latest health challenges. In our most recent sprint we discussed “How to Overcome the Blockers to DTx Adoption and Measure Success.”  In this blog we’ve pulled out the top takeaways from this series.

5 key recommendations:

#1 Have a clear value proposition of the solution: To ensure adoption of a DTx product, the solution needs to provide health benefits to the patient. Demonstrating health benefits will drive adoption across patients, HCPs and providers alike. Clinical evidence and regulatory clearance are important in ensuring trust and demonstrating health benefits of a DTx solution. This will also encourage early adopters to implement the DTx solution. If the value proposition, particularly the product’s ability to drive revenue is clear, providers are more likely to use their own resources to promote the product, including facilitating clinical research and obtaining regulatory approval, thus increasing adoption.

#2 Providing a method of time-reduction for HCPs is critical for success: There are several factors that will encourage HCPs use of a DTx product. As achieving patient outcomes is critical, social incentives should be focused on improving patient care and treatment. However, the ultimate factor that is required to ensure HCP adoption is to provide a means to enhance time management. Solutions which aid time management should focus not just on reducing time spent with patients, but rather on the ability to provide clinical leverage through enhanced clinical decision making, greater efficiency in the clinical delivery workflow, improving patient outcomes, and enabling high-quality time spent with patients and families.

#3 Providing facilitators of adherence will promote patient engagement: To ensure patient adoption, the products need to be engaging and interactive. Some such methods of engagement include personalisation, gamification, human interaction and an emotional attachment to the product. ‘Freemium’ D2C solutions offer higher levels of flexibility than regulatory approved solutions, and can demonstrate high levels of adoption in the short term. However, maintaining patient engagement for these solutions is difficult, even if facilitators of adherence are incorporated into the solution. Thus, although regulatory approval may reduce flexibility, it may be required for DTx solutions to maintain high levels of patient engagement, as well as increasing the likelihood of funding.

#4 Increasing awareness around the pivotal influence that DTx can play in sustainable healthcare models may increase adoption: Traditional healthcare systems are reactive. As average life expectancy soars and prevalence of debilitating diseases grow, global health expenditure is increasing in parallel. The long term sustainability of these reactive systems are under question, and models which are instead holistic and preventive may be imperative in the future of healthcare. DTx can play a key role in these systems, particularly in the P4 (Predictive, Preventative, Personalized and Participatory) model. Currently, there is little consideration given to the long-term cost effectiveness of adopting DTx solutions. As healthcare systems evolve, demonstrating the long-term efficacy that DTx can offer may ameliorate adoption.

#5 Digital solution providers need to work backwards from reimbursement

Typically, DTx companies will only focus on the reimbursement pathway after their DTx solutions have been validated. In this sense, the companies commit to achieving clinical efficiency and outcomes, but then struggle to achieve a suitable pathway for reimbursement. As the current reimbursement incentives, such as DiGA, are negligible for HCPs, adoption continues to be a challenge. However, as DiGA and other reimbursement pathways are optimised, HCPs may favour reimbursable DTx solutions. Therefore, achieving reimbursement will be an important component of the DTx to raise HCP adoption rates. To achieve reimbursement and overcome barriers to adoption, DTx companies should consider the pathway to reimbursement concurrently with clinical and regulatory pathways.

Experts Included:

Adriano Garcez (Director, Outcomes Research, ZS), Hannes Klopper (CEO, HelloBetter), Katerina Gaitani (Global Brand Leader, Bayer), Mette Dyhrberg (Founder & CEO, Mymee), Nemanja Kovacev, MD, PhD (MedTech Expert, HTEC Group), Ricardo Berrios (Executive Founder, Adhera Health), Richard DeNunzio (Chief Commercial Officer, Click Therapeutics), Richie Bavasso (CEO, nQ Medical)

*All opinions are the participants’ own and do not necessarily reflect the stance of their respective employers.

Want to join the conversation? Check here for upcoming meetings and events.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

Ready to read more? HealthXL members can access the full peak of the report on the HealthXL Community Hub.

Not yet a member of HealthXL? Download your 11 page snapshot of the report.

Download your 11 page snapshot

Connect with peers and share insights

Don't miss out on the discussion of the latest insights and reports on digital health. Meet with peers and take a deep dive for 75 minutes. Unlike at webinars, you can freely exchange experiences and insights to solve challenges and design the future of DTx.

Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Masterclass: Key Considerations for Inclusion on the Evernorth Digital Health Formulary

13th December @ 10:45AM EDT

How do DTx products get listed on a formulary? And what happens next? Join this masterclass to hear from Mark Bini, the visionary who helped devise Evernorth's Digital Health Formulary.

Featuring
Mark Bini
Mark Bini
Chief Patient Experience Officer at Evernorth
Featuring
Mark Bini
Mark Bini
Chief Patient Experience Officer at Evernorth
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Masterclass: Future EU Regulations for AI in Medical Devices

13th December @ 10AM GMT / 6PM AWST

Are you trying to commercialize AI-based digital health solutions in the European Union (EU)? Would you like to learn practical steps on how to navigate the EU regulations for AI in medical devices? Join us in this masterclass led by Erik Vollebregt (Partner at Axon Lawyers) to deep dive into this topic.

Featuring
Erik Vollebregt
Erik Vollebregt
Partner, Axon Lawyers
Featuring
Erik Vollebregt
Erik Vollebregt
Partner, Axon Lawyers
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Innovative Distribution Strategies for DTx

14th December @ 10:45 AM EDT

Currently, there is no one-size-fits-all strategy for DTx distribution. Join HealthXL in this meeting to discuss this topic further with your peers working in this space.

Featuring
Francesca Wuttke
Francesca Wuttke
CEO and Founder, nen Health
Featuring
Francesca Wuttke
Francesca Wuttke
CEO and Founder, nen Health
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Masterclass: DTx Access Negotiation and Contracting with Commercial Health Plans in the US

15th December @ 10:45 AM EDT

Are you seeking reimbursement of a DTx solution in the US? Join this Masterclass led by Mike Pace to deep dive into this topic with your peers working in this space.

Featuring
Michael Pace
Michael Pace
CEO & Founder at PalmHealth.co
Featuring
Michael Pace
Michael Pace
CEO & Founder at PalmHealth.co

Are you a HealthXL Member? See the Full Report Here

Non-HealthXL Member? You can purchase the report HERE

HealthXL Digital Health Meetings

Want to join the discussion now?

Join our Digital Health Meetings and take a deep dive for 75 minutes into topics like digital therapeutics, patient support, telehealth, clinical trials, dermatology and many more. These Meetings are not regular webinars: No audience, no recording and no hiding behind a screen. You actively participate in a discussion to solve your present challenges and design the future of digital health. And with a free account on our Community Hub, you stay connected and up-to-date on the latest news and insights, allowing you to fully immerse yourself in the topic before, during and after.

Telemedicine & Virtual Care Delivery
12th December @ 10:45AM EDT

Masterclass: Partnering with Health Systems in Digital Health

Are you working in digital health and looking for successful partnerships with health systems? Join this meeting to deep dive into this topic with other senior leaders in this field.

Michael Freni
Featuring
Michael Freni
Vice President, Business Development, Innovation & Venture Partner, A.I. Digital Innovation Fund, Mass General Brigham
Digital Therapeutics (DTx)
13th December @ 10:45AM EDT

Masterclass: Key Considerations for Inclusion on the Evernorth Digital Health Formulary

How do DTx products get listed on a formulary? And what happens next? Join this masterclass to hear from Mark Bini, the visionary who helped devise Evernorth's Digital Health Formulary.

Mark Bini
Featuring
Mark Bini
Chief Patient Experience Officer at Evernorth
Digital Therapeutics (DTx)
13th December @ 10AM GMT / 6PM AWST

Masterclass: Future EU Regulations for AI in Medical Devices

Are you trying to commercialize AI-based digital health solutions in the European Union (EU)? Would you like to learn practical steps on how to navigate the EU regulations for AI in medical devices? Join us in this masterclass led by Erik Vollebregt (Partner at Axon Lawyers) to deep dive into this topic.

Erik Vollebregt
Featuring
Erik Vollebregt
Partner, Axon Lawyers
Digital Therapeutics (DTx)
14th December @ 10:45 AM EDT

Innovative Distribution Strategies for DTx

Currently, there is no one-size-fits-all strategy for DTx distribution. Join HealthXL in this meeting to discuss this topic further with your peers working in this space.

Francesca Wuttke
Featuring
Francesca Wuttke
CEO and Founder, nen Health

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.